SG11201803920TA - Compounds and compositions useful for treating disorders related to ntrk - Google Patents
Compounds and compositions useful for treating disorders related to ntrkInfo
- Publication number
- SG11201803920TA SG11201803920TA SG11201803920TA SG11201803920TA SG11201803920TA SG 11201803920T A SG11201803920T A SG 11201803920TA SG 11201803920T A SG11201803920T A SG 11201803920TA SG 11201803920T A SG11201803920T A SG 11201803920TA SG 11201803920T A SG11201803920T A SG 11201803920TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ntrk
- cambridge
- street
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau (43) International Publication Date ..... .....r .,„01 26 May 2017(26.05.2017) WIPO I PCT ID Hit (10) WO International 2017/087778 111111111111111111IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIMIIIIIIIIIIIIIII Publication Al Number (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C07D 487/04 (2006.01) A61K 31/519 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/062731 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 18 November 2016 (18.11.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/257,476 19 November 2015 (19.11.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: BLUEPRINT MEDICINES CORPORA- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TION [US/US]; 38 Sidney Street, Suite 200, Cambridge, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MA 02139 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: WENGLOWSKY, Steven, Mark; 266 Har- GW, KM, ML, MR, NE, SN, TD, TG). yard Street, Apt 6, Cambridge, MA 02139 (US). MIDU- TURU, Chandrasekhar, V.; 348 Harvard Street, Apt. #2, Declarations under Rule 4.17: Cambridge, MA 02138 (US). BIFULCO, Neil, Jr; 15 Lil- as to applicant's entitlement to apply for and be granted a lian Ave, Sudbury, MA 01776 (US). KIM, Joseph, L.; 20 patent (Rule 4.170) Green Way, Wayland, MA 01778 (US). — as to the applicant's entitlement to claim the of the priority (74) Agent: MCCARTY, Catherine, M.; Lando & Anastasi, earlier application (Rule 4.17 (iii)) — LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). Published: — with international search report (Art 21(3)) (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, Il .4t Ge IN IN IN Ge C::: , IN l'I C::: , N (54) Title: COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK P (57) : This invention relates to inhibitors of NTRK comprising a pyrazolo[1,5-4]pyrimidine-3-carbonitrile structure. They P. are active against wild-type NTRK and its resistant mutants.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257476P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/062731 WO2017087778A1 (en) | 2015-11-19 | 2016-11-18 | Compounds and compositions useful for treating disorders related to ntrk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803920TA true SG11201803920TA (en) | 2018-06-28 |
Family
ID=57517997
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912607SA SG10201912607SA (en) | 2015-11-19 | 2016-11-18 | Compounds and compositions useful for treating disorders related to ntrk |
| SG11201803920TA SG11201803920TA (en) | 2015-11-19 | 2016-11-18 | Compounds and compositions useful for treating disorders related to ntrk |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912607SA SG10201912607SA (en) | 2015-11-19 | 2016-11-18 | Compounds and compositions useful for treating disorders related to ntrk |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10370379B2 (en) |
| EP (1) | EP3377497A1 (en) |
| JP (1) | JP2019500328A (en) |
| KR (1) | KR20180081790A (en) |
| CN (1) | CN108431008A (en) |
| AR (1) | AR106756A1 (en) |
| AU (1) | AU2016355196A1 (en) |
| BR (1) | BR112018010024A8 (en) |
| CA (1) | CA3005741A1 (en) |
| HK (1) | HK1259453A1 (en) |
| IL (1) | IL259164A (en) |
| MX (1) | MX2018006195A (en) |
| PH (1) | PH12018501065A1 (en) |
| RU (1) | RU2018122089A (en) |
| SG (2) | SG10201912607SA (en) |
| TW (1) | TWI733713B (en) |
| WO (1) | WO2017087778A1 (en) |
| ZA (1) | ZA201803530B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019102203A (en) | 2012-07-11 | 2019-03-05 | Блюпринт Медсинс Корпорейшн | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| LT3057969T (en) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PL3395814T3 (en) | 2013-10-25 | 2022-08-22 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| KR20180048635A (en) | 2015-07-24 | 2018-05-10 | 블루프린트 메디신즈 코포레이션 | Compositions useful for treating disorders related to KIT and PDGFR |
| JP6877407B2 (en) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Compounds and compositions useful for the treatment of NTRK-related disorders |
| MX2018005528A (en) | 2015-11-02 | 2018-11-09 | Blueprint Medicines Corp | Inhibitors of ret. |
| CN108431008A (en) | 2015-11-19 | 2018-08-21 | 蓝图药品公司 | It can be used for treating the compound and composition with the relevant illnesss of NTRK |
| AR107912A1 (en) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | RET INHIBITORS |
| CA3020870A1 (en) | 2016-04-15 | 2017-10-19 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| US20210100795A1 (en) | 2018-04-03 | 2021-04-08 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| MX2021004769A (en) | 2018-10-30 | 2021-08-24 | Kronos Bio Inc | Compounds, compositions, and methods for modulating cdk9 activity. |
| CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
| AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| CN112979654B (en) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业（成都）有限公司 | Heteroaryl fused ring compounds, preparation method and application thereof |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5251911A (en) | 1992-12-09 | 1993-10-12 | Blake Carlton E | Safety construction for passenger vehicle |
| EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
| PL224879B1 (en) * | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| AU2005230818B2 (en) | 2004-04-02 | 2010-11-25 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| PT2350071E (en) | 2008-10-22 | 2014-04-11 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| CA2761074A1 (en) | 2010-05-05 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| US8637516B2 (en) * | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (en) * | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | Antitumor effect and application of alicyclic structure-containing compound |
| RU2019102203A (en) | 2012-07-11 | 2019-03-05 | Блюпринт Медсинс Корпорейшн | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS |
| JP6223451B2 (en) | 2012-08-31 | 2017-11-01 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Cancer diagnosis and treatment methods |
| KR20150072412A (en) * | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 inhibitors |
| AU2013337277B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| TWI629266B (en) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | Inhibitors of the fibroblast growth factor receptor |
| CN105377845B (en) | 2013-02-01 | 2017-11-24 | 拜耳制药股份公司 | Substituted pyrazolopyrimidine base Aminoindazole class |
| CN103965199B (en) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | A kind of heteroaromatic compounds, the medical composition and its use comprising it |
| WO2014130375A1 (en) * | 2013-02-21 | 2014-08-28 | Calitor Sciences, Llc | Heteroaromatic compounds as pi3 kinase modulators |
| US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| LT3057969T (en) | 2013-10-17 | 2018-07-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PL3395814T3 (en) | 2013-10-25 | 2022-08-22 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108328A1 (en) * | 2014-01-14 | 2015-07-23 | 주식회사 엘지생명과학 | Novel ntrk1 fusion gene as colorectal cancer marker and use thereof |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2015157093A1 (en) * | 2014-04-08 | 2015-10-15 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| JP6609631B2 (en) | 2014-12-15 | 2019-11-20 | シーエムジー ファーマシューティカル カンパニー，リミテッド | Fused ring heteroaryl compounds and uses as TRK inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| WO2016133838A1 (en) | 2015-02-20 | 2016-08-25 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| KR20180048635A (en) | 2015-07-24 | 2018-05-10 | 블루프린트 메디신즈 코포레이션 | Compositions useful for treating disorders related to KIT and PDGFR |
| JP6877407B2 (en) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Compounds and compositions useful for the treatment of NTRK-related disorders |
| MX2018005528A (en) | 2015-11-02 | 2018-11-09 | Blueprint Medicines Corp | Inhibitors of ret. |
| CN108431008A (en) | 2015-11-19 | 2018-08-21 | 蓝图药品公司 | It can be used for treating the compound and composition with the relevant illnesss of NTRK |
| AR107912A1 (en) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | RET INHIBITORS |
| CA3020870A1 (en) | 2016-04-15 | 2017-10-19 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| CN110022900A (en) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | The combination of fibroblast growth factor receptor 4 inhibitor and cell cycle protein dependent kinase inhibitor |
| CN107844168B (en) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | Mainboard assembly and fastening device thereof |
-
2016
- 2016-11-18 CN CN201680077637.8A patent/CN108431008A/en active Pending
- 2016-11-18 US US15/355,425 patent/US10370379B2/en active Active
- 2016-11-18 SG SG10201912607SA patent/SG10201912607SA/en unknown
- 2016-11-18 SG SG11201803920TA patent/SG11201803920TA/en unknown
- 2016-11-18 EP EP16808868.0A patent/EP3377497A1/en not_active Withdrawn
- 2016-11-18 CA CA3005741A patent/CA3005741A1/en not_active Abandoned
- 2016-11-18 BR BR112018010024A patent/BR112018010024A8/en not_active IP Right Cessation
- 2016-11-18 MX MX2018006195A patent/MX2018006195A/en unknown
- 2016-11-18 WO PCT/US2016/062731 patent/WO2017087778A1/en active Application Filing
- 2016-11-18 AU AU2016355196A patent/AU2016355196A1/en not_active Abandoned
- 2016-11-18 AR ARP160103546A patent/AR106756A1/en unknown
- 2016-11-18 RU RU2018122089A patent/RU2018122089A/en not_active Application Discontinuation
- 2016-11-18 TW TW105137936A patent/TWI733713B/en not_active IP Right Cessation
- 2016-11-18 JP JP2018525688A patent/JP2019500328A/en not_active Ceased
- 2016-11-18 KR KR1020187016321A patent/KR20180081790A/en unknown
-
2018
- 2018-05-06 IL IL259164A patent/IL259164A/en unknown
- 2018-05-17 PH PH12018501065A patent/PH12018501065A1/en unknown
- 2018-05-28 ZA ZA2018/03530A patent/ZA201803530B/en unknown
-
2019
- 2019-02-01 HK HK19101858.8A patent/HK1259453A1/en unknown
- 2019-07-31 US US16/527,773 patent/US11059827B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108431008A (en) | 2018-08-21 |
| RU2018122089A (en) | 2019-12-25 |
| TWI733713B (en) | 2021-07-21 |
| PH12018501065A1 (en) | 2019-01-28 |
| BR112018010024A8 (en) | 2019-02-26 |
| KR20180081790A (en) | 2018-07-17 |
| SG10201912607SA (en) | 2020-02-27 |
| US20190382410A1 (en) | 2019-12-19 |
| CA3005741A1 (en) | 2017-05-26 |
| TW201720826A (en) | 2017-06-16 |
| BR112018010024A2 (en) | 2018-11-21 |
| AR106756A1 (en) | 2018-02-14 |
| WO2017087778A1 (en) | 2017-05-26 |
| IL259164A (en) | 2018-06-28 |
| US10370379B2 (en) | 2019-08-06 |
| US20170145018A1 (en) | 2017-05-25 |
| AU2016355196A1 (en) | 2018-06-21 |
| MX2018006195A (en) | 2018-09-05 |
| EP3377497A1 (en) | 2018-09-26 |
| JP2019500328A (en) | 2019-01-10 |
| US11059827B2 (en) | 2021-07-13 |
| ZA201803530B (en) | 2021-08-25 |
| HK1259453A1 (en) | 2019-11-29 |
| RU2018122089A3 (en) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases |